ANDA Approval for EirGen Product EIR-060

EirGen Pharma are delighted to announce that our product EIR-060 has received approval from US FDA as of yesterday. EIR-060 is indicated for the treatment of various forms of brain tumours and is a very important approval for EirGen as it represents another product taken through our R&D pipeline to approval. This is a highly significant milestone we have achieved as a result of a joint effort over many years by a lot of people and our partner expects to commence marketing of the product shortly.